{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '9.2.3.4 Physical Examination', 'Physical examinations will include an assessment of general appearance, skin, eyes,', 'ear/nose/throat, heart, chest, abdomen, reflexes, lymph nodes, spine, and extremities, including', 'menstruation status (Section 7.2.3). All deviations from normal will be recorded, including those', \"attributable to the patient's disease. Refer to Section 1.2 Study Flow Chart for the schedule of\", 'physical examination performed throughout this study.', '9.2.3.5 Clinical Laboratory Safety Variables', 'The clinical laboratory tests will be conducted by an accredited (College of American Pathologists', 'or equivalent) central laboratory with national and regional clinical licenses as required for', 'diagnostic testing and must provide evidence of participation in proficiency testing, as', 'appropriate. After reviewing the laboratory report and evaluating any results that are outside the', 'normal range, the Investigator must sign and date the laboratory report.', 'Abnormal laboratory values that are considered to be clinically significant by the Investigator', 'should be repeated as soon as possible after receiving the laboratory report to rule out laboratory', 'error. Persistent abnormal laboratory values should be repeated until they return to normal or until', 'an etiology of the persistent abnormality is determined.', 'Refer to Section 1.2 Study Flow Chart for the description of the clinical laboratory evaluations', 'and the schedule of laboratory evaluations performed throughout this study.', 'The clinical laboratory parameters that will be measured in safety hematology and chemistry', 'blood samples are:', 'Hematology: To include hemoglobin, hematocrit, platelet count, total white blood cell', 'count with five-part differential count, and total red blood cell count.', 'Serum chemistry: To include: creatinine, blood urea nitrogen, glucose, uric acid, total', 'cholesterol, total protein, albumin, total bilirubin (in case of values above the normal', 'range, differentiation in conjugated and non-conjugated bilirubin), ALT, AST, alkaline', 'phosphatase (ALP), lactate dehydrogenase, electrolytes (sodium, potassium, chloride),', \"bicarbonate, and CPK. Patients' fasting or non-fasting status at blood sample collection\", 'will be recorded on the Central Laboratory Requisition Form. Fasting is considered as no', 'intake of food or any drink except for water for at least 8 hours.', 'Urine dipstick analysis including specific gravity, pH, glucose, ketones, blood, protein,', 'nitrate, leukocyte esterase, urobilinogen and bilirubin (by dipstick). If any parameter on', 'the dipstick is abnormal, a urine sample should be sent to the central laboratory for testing.', 'If positive for proteins, microscopic analysis is performed by central laboratory.', 'Clinical laboratory testing at Screening Visit 1 will include HBs-Ag, hepatitis B surface', 'antibody (HBs-Ab), HBc-Ab, HCV-Ab, HIV screen (Anti-HIV-1 and HIV-2 antibodies)', 'and anti-nuclear antibody (ANA).', 'Property of the Sanofi Group - strictly confidential', 'Page 67', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Table 1 - Eligibility interpretation for hepatitis serology', 'Hepatitis Serology Result', 'Protocol Action', 'HBs Ag positive or indeterminate', 'Excluded', 'HBs Ab positive, HBs Ag negative, HBc Ab negative', 'Eligible', 'IgM HBc Ab positive', 'Excluded', 'Total-HBc Ab positive (with or without HBs Ab positive)', 'Test for HBV DNA', 'If HBV DNA positive: excluded', 'If HBV DNA negative/not detecteda eligible', 'HCV antibody positive', 'Test for HCV RNA', 'If HCV RNA positive: excluded', 'If HCV RNA negative/not detected: eligible', 'a', 'It is recommended that patients who are receiving potentially immunosuppressive therapy and are IgG HBcAb positive and HBV DNA', 'negative undergo surveillance HBV DNA studies every 1-3 months depending upon the individual potential therapeutic risk and', 'comorbidities. If necessary, a hepatologist should be consulted on a case-by-case basis.', 'HBc Ab: Hepatitis B core antibody; HBs Ab: HBs Ab: Hepatitis B surface antibody; HBs Ag: Hepatitis B surface antigen; HBV DNA: Hepatitis B', 'virus DNA; HCV RNA: Hepatitis C virus RNA.', 'Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in', 'Appendix K.', '9.2.3.6 Other Safety Laboratory Tests', '9.2.3.6.1 Serum Immunoglobulins and Subtypes', 'Serum immunoglobulins: quantitative immunoassays for total IgG, IgG subclasses 1-4, IgM, and', 'IgA.', 'Please note that Total IgE, antigen-specific IgE, and antigen-specific IgG4 are assessed as', 'pharmacodynamic parameters (eg, to determine the change from Baseline in IgE/IgG4 ratio; see', 'Section 9.4.2).', 'As a precaution for maintenance of treatment blinding, results for immunoglobulins will not be', 'released to Investigators during the study, unless required for investigation of other safety findings', 'in individual patients.', '9.2.3.7 Pregnancy Test', 'A urine pregnancy test will be performed at Screening (Visit 1) in female patients of childbearing', 'potential who have commenced menstruating, and a urine dipstick pregnancy test will be', 'performed at Visit 2 prior to randomization and other clinic visits prior to administration of IMP.', 'A negative result must be obtained at Visit 1 and 2 prior to randomization. Refer to Section 1.2', 'Study Flow Chart for the schedule of pregnancy tests performed throughout this study. Those', 'female patients who commence initial menstruation during the study will be similarly monitored', 'with urine dipstick pregnancy tests and contraception consulting for the duration of the study.', 'Property of the Sanofi Group - strictly confidential', 'Page 68', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}